Cargando…

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration

OBJECTIVES: To evaluate functional and anatomical responses to intravitreal aflibercept (IVA) treatment in newly diagnosed and untreated neovascular age-related macular degeneration (nvAMD) cases and to investigate the effect of baseline lesion characteristics on anatomical responses. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Kıyat, Pelin, Menteş, Jale, Nalçacı, Serhad, Afrashi, Filiz, Barış, Mine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251674/
https://www.ncbi.nlm.nih.gov/pubmed/34187151
http://dx.doi.org/10.4274/tjo.galenos.2020.52460
_version_ 1783717136439443456
author Kıyat, Pelin
Menteş, Jale
Nalçacı, Serhad
Afrashi, Filiz
Barış, Mine
author_facet Kıyat, Pelin
Menteş, Jale
Nalçacı, Serhad
Afrashi, Filiz
Barış, Mine
author_sort Kıyat, Pelin
collection PubMed
description OBJECTIVES: To evaluate functional and anatomical responses to intravitreal aflibercept (IVA) treatment in newly diagnosed and untreated neovascular age-related macular degeneration (nvAMD) cases and to investigate the effect of baseline lesion characteristics on anatomical responses. MATERIALS AND METHODS: This prospective, cross-sectional study included a series of 139 eyes of 133 patients that were diagnosed with active nvAMD and had not been treated. All eyes were subjected to complete ophthalmological examination, spectral-domain optical coherence tomography and fluorescein angiography, and 42 eyes also underwent indocyanine green angiography. IVA treatment was performed using a “treat and extend” regimen after 3 injections at 4-6 weeks intervals. Anatomical and functional responses at 4 weeks after the last injection were evaluated in eyes that completed 3 injections and the subgroup of eyes that completed 6 IVA injections. The effect of baseline lesion characteristics on IVA treatment results was also investigated. RESULTS: All 139 eyes included in the study received 3 IVA injections (group 1) and 62 received 6 IVA injections. Both groups showed statistically significant improvement in best-corrected visual acuity (p<0.001 for both). The rate of complete response was 54.6% and 58.0% in groups 1 and 2, respectively. In group 1, the presence of pigment epithelial detachment (PED) and serous PED were identified as negative initial factors (p=0.043, p=0.005, respectively). However, none of the baseline characteristics were significantly associated with anatomical response in group 2. CONCLUSION: In our study, it was determined that successful anatomical and functional results were achieved with 3 and 6 doses of IVA in eyes with newly-diagnosed and untreated nvAMD. Among baseline characteristics, the presence of PED and serous PED in particular were found to be factors affecting treatment response negatively.
format Online
Article
Text
id pubmed-8251674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-82516742021-07-13 Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration Kıyat, Pelin Menteş, Jale Nalçacı, Serhad Afrashi, Filiz Barış, Mine Turk J Ophthalmol Original Article OBJECTIVES: To evaluate functional and anatomical responses to intravitreal aflibercept (IVA) treatment in newly diagnosed and untreated neovascular age-related macular degeneration (nvAMD) cases and to investigate the effect of baseline lesion characteristics on anatomical responses. MATERIALS AND METHODS: This prospective, cross-sectional study included a series of 139 eyes of 133 patients that were diagnosed with active nvAMD and had not been treated. All eyes were subjected to complete ophthalmological examination, spectral-domain optical coherence tomography and fluorescein angiography, and 42 eyes also underwent indocyanine green angiography. IVA treatment was performed using a “treat and extend” regimen after 3 injections at 4-6 weeks intervals. Anatomical and functional responses at 4 weeks after the last injection were evaluated in eyes that completed 3 injections and the subgroup of eyes that completed 6 IVA injections. The effect of baseline lesion characteristics on IVA treatment results was also investigated. RESULTS: All 139 eyes included in the study received 3 IVA injections (group 1) and 62 received 6 IVA injections. Both groups showed statistically significant improvement in best-corrected visual acuity (p<0.001 for both). The rate of complete response was 54.6% and 58.0% in groups 1 and 2, respectively. In group 1, the presence of pigment epithelial detachment (PED) and serous PED were identified as negative initial factors (p=0.043, p=0.005, respectively). However, none of the baseline characteristics were significantly associated with anatomical response in group 2. CONCLUSION: In our study, it was determined that successful anatomical and functional results were achieved with 3 and 6 doses of IVA in eyes with newly-diagnosed and untreated nvAMD. Among baseline characteristics, the presence of PED and serous PED in particular were found to be factors affecting treatment response negatively. Galenos Publishing 2021-06 2021-06-29 /pmc/articles/PMC8251674/ /pubmed/34187151 http://dx.doi.org/10.4274/tjo.galenos.2020.52460 Text en © Copyright 2021 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kıyat, Pelin
Menteş, Jale
Nalçacı, Serhad
Afrashi, Filiz
Barış, Mine
Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title_full Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title_fullStr Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title_full_unstemmed Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title_short Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
title_sort aflibercept treatment results and association with baseline characteristics in cases of newly diagnosed neovascular age-related macular degeneration
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251674/
https://www.ncbi.nlm.nih.gov/pubmed/34187151
http://dx.doi.org/10.4274/tjo.galenos.2020.52460
work_keys_str_mv AT kıyatpelin aflibercepttreatmentresultsandassociationwithbaselinecharacteristicsincasesofnewlydiagnosedneovascularagerelatedmaculardegeneration
AT mentesjale aflibercepttreatmentresultsandassociationwithbaselinecharacteristicsincasesofnewlydiagnosedneovascularagerelatedmaculardegeneration
AT nalcacıserhad aflibercepttreatmentresultsandassociationwithbaselinecharacteristicsincasesofnewlydiagnosedneovascularagerelatedmaculardegeneration
AT afrashifiliz aflibercepttreatmentresultsandassociationwithbaselinecharacteristicsincasesofnewlydiagnosedneovascularagerelatedmaculardegeneration
AT barısmine aflibercepttreatmentresultsandassociationwithbaselinecharacteristicsincasesofnewlydiagnosedneovascularagerelatedmaculardegeneration